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esponsibility of Xi’Abstract Combination of asenapine with valproic acid received regulatory approval for acute treatment
of schizophrenia and maniac episodes of bipolar disorders. A simple LC–MS/MS method was developed
and validated for simultaneous quantiﬁcation of asenapine and valproic acid in human plasma. Internal
standards were added to 300 μL of plasma sample prior to liquid–liquid extraction using methyl tertiary
butyl ether (MTBE). Chromatographic separation was achieved on Phenomenex C18 column
(50 mm 4.6 mm, 5 μm) in isocratic mode at 40 1C. The mobile phase used was 10 mM ammonium
formate–acetonitrile (5:95, v/v) at a constant ﬂow rate of 0.8 mL/min monitored on triple quadrupole mass
spectrometer, operating in the multiple reaction monitoring (MRM) mode. The injection volume used for
LC–MS/MS analysis was 15 μL and the run time was 2.5 min. These low run time and small injection
volume suggest the high efﬁciency of the proposed method. The method was validated over the
concentration range of 0.1–10.02 ng/mL and 10–20,000 ng/mL for asenapine and valproic acid
respectively. The method recoveries of asenapine (81.33%), valproic acid (81.70%), gliclazide
(78.45%) and benzoic acid (79.73) from spiked plasma samples were consistent and reproducible. The
application of this method was demonstrated by a pharmacokinetic study in 8 healthy male volunteers
with 5 mg asenapine and 250 mg valproic acid administration.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.sity. Production and hosting by Else
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an Jiaotong University.1. Introduction
The common psychiatric disorders such as schizophrenia and
bipolar disorder are very devastating, characterized by manic/
hypomanic, depressed or mixed states, and associated with a high
risk for suicide [1,2]. Although manic episodes are considered as
the hallmark state of bipolar disorder and it is depression that
primarily contributes to functional disability and high rates ofvier B.V. All rights reserved.
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that bipolar affective disorders rank within the top 10 causes of
disability among all medical conditions, as measured in years lived
with disability [6]. Although a number of treatment options have
been established for acute manic or mixed episodes, including
most currently used atypical antipsychotics. Asenapine is indicated
in the European Union for the treatment of moderate to severe
manic episodes associated with bipolar I disorder [7]. The multi-
receptor pharmacologic proﬁle of asenapine includes antagonism
at serotonergic 5-HT2A and adrenergic receptors [8] suggesting
that it may effectively treat depressive symptoms. Asenapine is an
antipsychotic with a unique pharmacologic proﬁle indicated in the
United States in adults for treatment of schizophrenia and as
monotherapy or adjunctive therapy with valproate/valproic acid in
the treatment of manic or mixed episodes associated with bipolar I
disorder [9,10]. Asenapine is approved in August 2009 by US
FDA for the acute treatment of schizophrenia and maniac episodes
of bipolar disorders. Asenapine belongs to the class dibenzo-
oxepino pyrroles, it is a white to off-white powder. The chemical
designation is (3aRS, 12bRS)-5-Chloro-2-methyl2, 3, 3a, 12b-
tetrahydro-1Hdibenzo [2, 3:6, 7] oxepino [4,5c] pyrrole (2Z)-2-
butenedioate (1:1). Its molecular formula is C17H16ClNO C4H4O4
and its molecular weight is 401.84 (free base: 285.8). Valproic
acid is one of only a few anticonvulsants that are approved by the
FDA for the treatment of mania in bipolar disorder. The chemical
structures of asenapine and valproic acid are shown in Fig. 1.
The coupling of HPLC with mass spectrometry (LC–MS/MS) is
now generally accepted as the preferred technique for quantifying
small molecule drugs, metabolites, and other xenobiotic biomole-
cules in biological matrices, since this technique is highly selective
and sensitive [11–14]. Literature survey revealed that only one
LC–MS/MS study has been reported for the quantiﬁcation of
asenapine in human plasma with solid phase extraction [15]. But
best of our knowledge no analytical method has been reported for
simultaneous determination of asenapine and valproic acid. Hence,
now we presented a sensitive and selective LC–MS/MS study for
simultaneous determination of asenapine and valproic acid in
human plasma using a simple and cost-effective liquid–liquid
extraction method. The developed bio-analytical method was
validated as per the FDA guidelines and applied to human
pharmacokinetic study in healthy male volunteers after oral
administration of asenapine and valproic acid [16].2. Materials and methods
2.1. Chemicals and reagents
All reagents used were of analytical grade or HPLC grade.
Ammonium formate and formic acid were purchased from
Mercks (Darmstadt, Germany). Methyl tertiary butyl ether wasFig. 1 Chemical structure of (A) asenapine and (B) valproic acid.obtained from Vetecs (Rio de Janeiro, Brazil). Acetonitrile was
acquired from Mercks (Darmstadt, Germany). Asenapine, val-
proic acid, benzoic acid and gliclazide (assigned purity 99.9%)
were purchased from United States Pharmacopoeia (USP). HPLC
grade water was prepared by Milli-Q reverse osmosis (Millipores,
Bedford, USA) and meets United States Pharmacopoeia require-
ments. Modiﬁed hydrophilic polytetra-ﬂuoroethylene membranes
with a pore size of 0.22 μm were used to ﬁlter the mobile phase
(Millipores, Bedford, USA) and Millexs syringe ﬁlters hydro-
philic polytetra-ﬂuoroethylene membranes (13 mm, 0.45 μm pore
size) from Millipores (Bedford, USA) were used to ﬁlter the
samples.
2.2. Instrumentation
The LC–MS/MS system used for method development and validation
was an Applied Biosystems MDS Sciex API 4000 model (Switzer-
land), coupled with HPLC system consisted of LC-20AD binary
gradient pump, SIL-10HTC auto sampler and a column oven CTO-
10ASVP (Shimadzu Corporation, Kyoto, Japan). Data acquisition
and processing were conducted using the Analyst 1.5.1 software on a
Dell computer (Digital equipment Co). The analytical column used
was Phenomenex C18 column (50 mm 4.6 mm, 5 μm). The LC
solvent program was operated in isocratic mode at 40 1C. Mobile
phase used was 10 mM ammonium formate–acetonitrile (5:95, v/v) at
a constant ﬂow rate of 0.8 mL/min. The LC eluate was split down to
0.2 mL/min and introduced into triple quadrupole MS/MS system
equipped with an electro spray ionization source. The MS/MS system
was operated in positive ion mode for asenapine and in negative
mode for valproic acid. The detailed mass spectrometer conditions are
as follows: vaporizer temperature (TEM) 500 1C, ionization spray
voltage +5500 V (asenapine) and −5000 V (valproic acid), collision
gas (CAD, nitrogen) 7 psi, curtain gas (CUR) 40 psi, nebulizer gas
(GS1) 35 and (GS2) 35 psi. The mass spectrometer was operated in
both positive and negative ion multiple reaction monitoring (MRM)
modes. The MRM transitions for analytes and IS are shown in
Table 1. The declustering potential (DP), collision energy (CE) and
other compound parameters for the analytes and IS were optimized
individually and are shown in Table 1 (It is anticipated that small
deviations in the masses (m/z70.5) could occur because of tuning
differences and the MS system used).
2.3. Preparation of calibration standards and quality control
samples
Standard stock solution and IS stock solutions of benzoic acid (IS
of valproic acid) and gliclazide (IS of asenapine) were prepared by
dissolving reference substances in mobile phase. Standard stock
solutions (asenapine 1.0 mg/mL, valproic acid 4.0 mg/mL) and IS
stock solution (benzoic acid 1.06 mg/mL, gliclazide 1.0 mg/mL)
were stored at approximately 4 1C. Standard curve and QC
samples were prepared by diluting stock solutions with blank
human plasma. The concentrations of standard curve and QC
samples are summarized in Table 2.
2.4. Preparation of mobile phase
Accurately weighed 0.639 g of ammonium formate was dissolved
in 1000 mL of Milli Q-water and ﬁltered through 0.22 mm
membrane ﬁlter paper. The mobile phase solution consisting of
ammonium formate and acetonitrile (5:95%, v/v) was prepared and
Table 1 Optimized parameters for MRM analysis of asenapine, valproic acid, gliclazide and benzoic acid.
Compound Transition (m/z) DP (V) EP (V) CE (eV) CXP (V)
Asenapine 286.3/229.2 80 10 33 22
Valproic acid 143.4/143.4 –65 10 –30 –20
Gliclazide (IS) 324.3/110.1 30 10 25 6
Benzoic acid (IS) 121.1/77.1 –35 –10 –25 –10
Table 2 Standard solution concentrations of asenapine and
valproic acid.
Standards
and QCs
Asenapine
(ng/mL)
Valproic acid
(ng/mL)
STD 1 0.10 10
STD 2 0.20 20
STD 3 0.34 50
STD 4 0.67 200
STD 5 1.34 800
STD 6 2.68 2000
STD 7 4.01 6000
STD 8 8.02 13,000
STD 9 10.02 20,000
LQC 0.29 50
MQC 3.54 7200
HQC 7.51 14,300
A.V.B. Reddy et al.396ﬁltered through nylon (0.22 mm) membrane sample ﬁlter paper and
degassed and then the solutions were stored at ambient
temperature.2.5. Sample procedure
Before to assay, frozen human plasma samples were thawed at
ambient temperature and centrifuged at 4500 rpm for 4 min at 5 1C
to precipitate solids. In the following order, 0.03 mL of IS work
solution (50 ng/mL gliclazide and 10,000 ng/mL benzoic acid) was
added into each glass tube except for blank plasma. 0.3 mL of
standards, QCs, study samples and blank plasma were transferred
into the glass tubes. After vortex for 3 min, 2.0 mL of methyl
tertiary butyl ether (MTBE) was transferred inward then tubes were
stoppered well and shaken vigorously for approximately 5 min.
Following centrifugation at 6000 rpm for 10 min, upper organic
phase was transferred out. Another 3.0 mL MTBE was added to
aqueous layer and the same extraction procedure was repeated.
The organic layers from two extraction procedures were mixed
together and evaporated to dryness under a slightly heated stream of
nitrogen at approximately 40 1C. The residue was reconstituted with
0.2 mL of mobile phase and 15 μL of sample was injected into LC–
MS/MS.2.6. Method validation
The developed analytical method was validated in accordance to
the recommendations published by the FDA.
System suitability experiment was performed by injecting six
consecutive injections at least once in a day with aqueous MQC
solution. System performance experiment was performed by injecting
sequence of injections at the beginning of analytical batch. Speciﬁcitywas determined by analyzing six blank human plasma samples
without adding IS to determine the interference with the analytes.
Matrix effects for analytes were evaluated by comparing the peak
areas of analyte in extracted samples of blank plasma from six
different drug-free volunteers spiked with known concentrations with
the corresponding peak areas obtained by direct injection of standard
solutions. Matrix effects for the IS were also investigated. The
interference between asenapine and valproic acid was observed. The
lowest standard on the calibration curve was accepted as the limit of
detection (LOD). The LOD was the concentration with signal-to-
noise ratio of 3.0. Six sets of calibration curves ranging from 0.1 to
10.02 ng/mL for asenapine, from 10 to 20,000 ng/mL for valproic
acid, respectively, were constructed by plotting the peak area ratios of
analyte/IS versus analyte concentrations in blank human plasma. The
intra-day precision and accuracy were estimated by analyzing six
replicates at three different QC levels. The inter-day precision was
determined by analyzing three level QC samples on six different runs.
The accuracy was expressed by (mean observed concentration)/
(spiked concentration) 100% and the precision by relative standard
deviation (R.S.D.). The extraction recoveries of asenapine and
valproic acid at three QC levels were determined by comparing peak
area of the analytes obtained from plasma samples with the analytes
spiked before extraction to those spiked after the extraction. QC
samples prepared to test stability were subjected to short-term (12 h)
at room temperature, 48 h autosampler at 1872 1C, 48 h refrigeration
at 4 1C, two freeze-thaw cycles at –7075 1C, and long-term at
–7075 1C for 30 days stability tests.
2.7. Application of the method to pharmacokinetic study
A pharmacokinetic study was conducted in healthy male subjects
(n¼8). The ethics committee approved the protocol and the volunteers
provided informed written consent. Blood samples were obtained
following oral administration of 5 mg of asenapine and 250 mg of
valproic acid. EDTA solution was used as an anti-coagulant and the
blood samples were collected at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5,
5.0, 5.5, 6.0, 12 and 18 h after oral administration of both drugs.
Plasma was separated from whole blood by centrifuging the blood
using a Heareuss model 1.0 R at 4000 rpm for 10 min, at 4 1C and
stored frozen at –7075 1C until analysis. Along with study samples,
QC samples at LQC, MQC, and HQC levels were assayed in duplicate
and were distributed among unknown samples in the analytical run.
Plasma concentration–time data of asenapine and valproic acid were
analyzed by noncompartmental method using WinNonlin version 5.1
(Pharsight Corporation, Mountain View, CA, USA).
3. Results and discussion
3.1. Sample preparation and LC–MS/MS analysis
The aim of the present study was to develop a rapid, selective and
sensitive analytical method including an efﬁcient and reproducible
Quantiﬁcation of asenapine and valproic acid in human plasma 397sample extraction step for quantitative analysis of asenapine and
valproic acid in human plasma. Based on our previous experience
on sample extraction for analyses, a simple and inexpensive
liquid–liquid extraction (LLE) procedure has been implemented
for the extraction of asenapine, valproic acid and IS from human
plasma. Ethyl acetate, MTBE, n-hexane, diethyl ether, n-hexane–
isopropanol (95:5, v/v), ethyl acetate–n-hexane (1:1, v/v), and
ethyl acetate–n-hexane (1:2, v/v), were all tested, and ﬁnally
MTBE was adopted because of its high extraction efﬁciency and
less interference.Fig. 3 Representative chromatograms for blank plasma of (A) ase
Fig. 2 Representative mass spectra of (A) asenapine, (BLiquid chromatography method development begins with
optimizing the mobile phase composition and column type. The
feasibility of several mixtures of solvents such as acetonitrile and
methanol using different buffers including ammonium acetate,
ammonium formate, acetic acid and formic acid were tested for
complete chromatographic resolution of asenapine, valproic acid
and IS. The versatility, suitability and robustness of the method
were checked with several C18 and Cyano (CN) columns. The
Phenomenex C18 column (50 mm 4.6 mm, 5 μm) provided very
good selectivity, sensitivity and peak shape for both analytes andnapine, (B) gliclazide, (C) valproic acid and (D) benzoic acid.
) gliclazide, (C) valproic acid and (D) benzoic acid.
A.V.B. Reddy et al.398IS, as compared to other columns. The mobile phase consisting of
10 mm ammonium formate–acetonitrile solution (5:95, v/v) with a
ﬂow rate of 0.8 mL/min was found to be suitable during LC
optimization. The retention times for asenapine and gliclazide (IS
for asenapine) were observed at 1.32 and 0.84 min, whereas for
valproic acid and benzoic acid they were 1.57 and 1.43 min
respectively.
In the MS method development, full-scan mass spectra of both
analytes and their IS were obtained in combination of positive and
negative ion modes with ESI source. Multiple reaction monitoring
mode was considered to obtain better selectivity. However, the
response found was much higher in negative ionization mode forFig. 4 Chromatograms of (A) plasma sample at LLOQ concentration and
valproic acid. (I) Asenapine, (II) gliclazide, (III) valproic acid and (IV) bevalproic acid compared to that in positive mode due to its acidic
nature. Valproic acid and benzoic acid (IS) were monitored by
MRM of deprotanated molecules at m/z 143.4–143.4 and m/z
121.1–77.1 respectively. The mass spectrometer was operated in
the positive ion MRM mode for asenapine in the LC–MS/MS
analysis. ESI spectra revealed higher signals at m/z 286.3 for
asenapine and m/z 324.3 for gliclazide. The full scan spectra were
dominated by protonated molecules [M+H]+. Additional tuning of
ESI source and collision-induced dissociation (CID) parameters
onto the transition m/z 286.3–229.2 (asenapine) and m/z 324.3–
110.1 (gliclazide) further improved the sensitivity. The represen-
tative mass spectra of analytes and internal standards are shown in(B) plasma sample 1.0 h after oral dose of 5 mg asenapine and 250 mg
nzoic acid.
Quantiﬁcation of asenapine and valproic acid in human plasma 399Fig. 2. Although the stable isotope labeled compounds of the
analytes would be the ideal IS, due to the lack of commercial
availability, the compounds with similar chromatographic, mass
spectrometric behavior and extraction characteristics were chosen
as IS. Therefore, gliclazide was chosen as IS for asenapine and
benzoic acid as IS for valproic acid.
3.2. Method validation parameters
3.2.1. Selectivity/speciﬁcity
Nanopure water was used to assess exogenous substances in blank
plasma with the lowest calibration curve sample. No signiﬁcant
interfering peaks were observed at the retention times of asenapine,
valproic acid and IS in blank plasma extraction, which are shown in
Fig. 3. No matrix effect for analytes (asenapine R.S.D.¼2.9%,
valproic acid R.S.D.¼3.4%) and IS (gliclazide R.S.D.¼4.4%,
benzoic acid R.S.D.¼5.1%) was observed for six different plasma
pools indicating that no undetected co-eluting compounds could
inﬂuence the ionization of the analytes. There was no interference
between asenapine and valproic acid from Fig. 4.3.2.2. Limit of quantiﬁcation and linearity
For this method, the lower limit of quantitation (LLQQ) was
0.1 ng/mL for asenapine, and 50 ng/mL for valproic acid. Repre-Table 3 Extraction recoveries of asenapine, valproic acid and intern
QCs Concentration (ng/mL)
LQC
Asenapine 0.29
Valproic acid 50
MQC
Asenapine 3.54
Valproic acid 7200
HQC
Asenapine 7.51
Valproic acid 14,300
IS
Gliclazide 50
Benzoic acid 10,000
an¼6.
bExtraction recovery (%) calculated as ratio of mean peak area of analyt
Table 4 Intra-day and inter-day precision and accuracy data of asen
QCs Concentration (ng/mL) Intra-day (n¼6)
Mean conc. (ng/mL) CV (%
LQC
Asenapine 0.29 0.260 1.93
Valproic acid 50.00 44.65 2.27
MQC
Asenapine 3.54 3.11 5.16
Valproic acid 7200.00 6364.80 4.27
HQC
Asenapine 7.51 6.82 3.13
Valproic acid 14,300.00 13,098.80 3.82sentative chromatograms of LLOQ and subject samples are shown
in Fig. 4. The correlation coefﬁcient (r2) value during the
validation (n¼6) was 40.998 for both asenapine and valproic
acid. The 9-point calibration curve was found to be linear over the
concentration range of 0.1–10.02 ng/mL for asenapine and 10–
20,000 ng/mL for valproic acid. After comparing the three
weighting models (x, 1/x and 1/x2), a regression equation with a
weighting factor of 1/x2 of the analyte to IS concentration was
found to produce the bestﬁt for the concentration–detector
response relationship for asenapine and valproic acid in human
plasma.3.2.3. Extraction recovery
The mean extraction recoveries of asenapine and valproic acid
were more than 81.3% and 81.7%, respectively. To IS, the mean
recoveries for gliclazide and benzoic acid were 78.4% and 79.7%,
respectively. The results are presented in Table 3. The extraction
recoveries were consistent over the entire concentration range and
comparable to the respective internal standard.3.2.4. Accuracy and precision
Data for intra-day and inter-day precision and accuracy of the
assay are summarized in Table 4. The intra-day accuracy rangedal standards from human plasmaa.
Recoveryb (%) CV (%)
84.72 2.11
81.21 4.37
80.40 4.01
82.60 5.74
78.91 3.48
81.34 5.21
78.45 4.12
79.73 3.24
es spiked into plasma before extraction to that of after extraction.
apine and valproic acid.
Inter-day (n¼6)
) Accuracy (%) Mean conc. (ng/mL) CV (%) Accuracy (%)
89.6 0.252 2.54 86.8
89.3 46.80 2.15 93.9
87.8 3.20 3.61 90.3
88.4 6595.20 2.48 91.9
90.8 6.53 5.31 86.9
91.6 12,626.90 4.81 88.3
A.V.B. Reddy et al.400between 87.8% and 90.8% with a precision of 1.93–5.16%, the
inter-day accuracy between 86.8% and 90.3% with a precision of
2.54–5.31% for asenapine. And the intra-day accuracy ranged
between 88.4% and 91.6% with a precision of 2.27–4.27%, the
inter-day accuracy between 88.3% and 93.9% with a precision of
2.15–4.81% for valproic acid.
3.2.5. Stability
The stability of asenapine and valproic acid was evaluated under
the conditions described in Table 5. The samples were stable under
these conditions. Therefore, in all cases the international accep-
tance criteria (variation values for area smaller than 15%) wereTable 5 Summary of stability studies of asenapine and valproic aci
Stability LQC (ng/mL) MQC
Asenapine Valproic acid Asena
0.29 50 3.54
Room temp (12 h)
Mean conc (n¼5) 0.264 46.04 3.61
CV (%) 3.11 3.41 1.84
Bias (%) –8.96 –7.90 1.97
Auto sampler (48 h)
Mean conc (n¼5) 0.273 48.27 3.47
CV (%) 3.41 2.54 5.21
Bias (%) –5.86 –3.45 –1.97
Short-term (12 h)
Mean conc (n¼5) 0.310 50.86 3.76
CV (%) 1.33 1.61 2.78
Bias (%) 6.89 1.72 6.21
Freeze-thaw
Mean conc (n¼5) 0.284 50.43 3.41
CV (%) 3.49 1.96 2.69
Bias (%) –2.06 0.85 –3.67
Long-term
Mean conc (n¼5) 0.271 48.70 3.29
CV (%) 5.73 2.57 3.32
Bias (%) –6.55 –2.59 –7.06
Fig. 5 Concentration–time proﬁle for 8 subjects after (I) 5 mgmet. Thus, the result presented was found to be within the
acceptable limits during the entire validation.
3.3. Application of the developed LC–MS/MS method
In order to verify the sensitivity and selectivity of the developed
method in a real-time situation, the method described in this paper
was applied to a human pharmacokinetic study that generated over
112 human plasma samples. Comparison of peak area ratio from the
unknown samples with that from calibration curve allowed quantita-
tion of the assayed samples. After oral administration of 5 mg of
asenapine and 250 mg of valproic acid tablets to the volunteers, thed in human plasma.
(ng/mL) HQC (ng/mL)
pine Valproic acid Asenapine Valproic acid
7200 7.51 14,300
6796.35 6.79 13,372.70
4.22 5.78 4.21
–5.61 –9.58 –6.47
7305.22 7.34 13,795.24
1.68 1.41 4.17
1.47 –2.63 –3.51
7293.72 7.12 13,658.20
1.23 3.14 2.19
1.31 –5.19 –4.48
6658.36 7.29 13,735.28
3.21 2.54 2.77
–7.50 –2.92 –3.87
6908.48 7.62 13,461.20
1.94 2.61 5.81
–4.03 1.46 –5.85
dosage of asenapine and (II) 250 mg dose of valproic acid.
Table 6 Pharmacokinetic data of asenapine and valproic
acid after their oral administration in 8 healthy male volunteers.
Parameter Asenapine Valproic acid
Cmax (ng/mL) 3.7671.18 15,82073270
Tmax (h) 1.0070.16 1.0770.48
t1/2 (h) 23.63711.8 3.4670.48
AUC0−18 (ng h/mL) 13.4272.91 19,4857640
AUC0−∞ (ng h/mL) 18.1575.73 106,27072140
Cmax: maximum plasma concentration.
Tmax: time point of maximum plasma concentration.
t1/2: half life of drug elimination during the terminal phase.
AUC0–18: area under the plasma concentration–time curve from
zero hour to 18 h.
AUC0–∞: area under the plasma concentration–time curve from
zero hour to inﬁnity.
Quantiﬁcation of asenapine and valproic acid in human plasma 401concentration versus time proﬁles for asenapine and valproic acid are
presented in Fig. 5. The resulted values are in good agreement with
the previously reported methods [15,17,18] and the pharmacokinetic
data of both asenapine and valproic acid are presented in Table 6.4. Conclusions
The selective LC–MS/MS method for the simultaneous determination
of asenapine and valproic acid in human plasma has been successfully
developed and validated. A simple and inexpensive liquid–liquid
extraction procedure and an isocratic chromatography condition using
a reversed-phase column provided an assay well suited for real-time
analyses. The method is adhered to the regulatory requirements for
selectivity, sensitivity, linearity, precision, accuracy, recovery, carry-
over, matrix effect and stability using a small sample volume 300 μL.
Because of the relative short chromatographic run time (2.5 min) and
straightforward sample pre-treatment procedure, the method is easy to
follow and can be adopted for clinical drug monitoring.
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